You are currently viewing a new version of our website. To view the old version click .
Neurology International
  • Neurology International is published by MDPI from Volume 12 Issue 3 (2020). Previous articles were published by another publisher in Open Access under a CC-BY licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
  • Review
  • Open Access

4 April 2018

Pantothenate Kinase-Associated Neurodegeneration: Clinical Aspects, Diagnosis and Treatments

,
,
,
,
and
1
Yasuj University of Medical Sciences, Yasuj, Iran
2
Iran University of Medical Sciences, Tehran, Iran
3
Kermanshah University of Medical Sciences, Kermanshah, Iran
*
Author to whom correspondence should be addressed.

Abstract

Pantothenate Kinase-Associated Neurodegeneration (PKAN) is an autosomal recessive disorder characterized by a mutation in the PANK2 gene. The clinical presentation may range from only speech disorder to severe generalized dystonia, spasticity, Visual loss, dysphagia and dementia. The hallmark of this disease is eyes of the tiger sign in the medial aspect of bilateral globus pallidus on T2-weighted MRI that is a hyperintense lesion surrounded by hypointensity. Common treatments for PKAN disease include anticholinergics, botulinum toxin, Oral and Intrathecal baclofen, Iron chelation drugs and surgical procedures such as ablative pallidotomy or thalamotomy, Deep brain stimulation. There are many controversies about the pathogenesis and treatment of this disease, and in recent years interesting studies have been done on PKAN disease and other similar diseases. This review summarizes the clinical presentation, etiology, imaging modalities and treatment.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.